Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT.W


Primary Symbol: V.TLT Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase Brain Cancer Pre-Clinical Research Accepted for Publication

Accesswire June 25, 2019

Theralase Releases Amended and Restated 1Q2019 Financial Statements

Accesswire June 18, 2019

Voltaic Minerals Corp. Receives Conditional TSXV Acceptance for Binding Letter of Intent with 1146915 B.C. Ltd.

Accesswire June 14, 2019

Theralase Releases 1Q 2019 Financial Statements

Accesswire May 30, 2019

Theralase Granted Notice of Acceptance for PhotoDynamic Compounds by Chinese Patent Office

Accesswire May 20, 2019

Theralase's 5th Annual Medical and Scientific Advisory Board Meeting Advances Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Accesswire May 13, 2019

Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy

Accesswire May 7, 2019

Theralase's Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study Research Presented at the American Urological Association

Accesswire May 6, 2019

Theralase Commences Phase II NMIBC Clinical Study

Accesswire April 25, 2019

Theralase's Latest Scientific Research to be Presented at the 17th Annual International Photodynamic Association World Congress

Accesswire April 22, 2019

Theralase(R) Releases 2018 Year End Audited Financial Statements

Accesswire April 17, 2019

Lightning Strikes Twice: A SECOND Patient Cancer-Free After 1 Year

Jeff Nielson April 3, 2019

Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment

Accesswire April 2, 2019

Theralase’s Phase IB Clinical Study to be Presented at the 17(th) International Photodynamic Association World Congress

Accesswire March 26, 2019

Theralase Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic Compounds

Accesswire March 4, 2019

Theralase Named to 2019 TSX Venture 50(TM)

Accesswire February 28, 2019

Theralase Announces Appointment of New Chief Executive Officers

Accesswire February 25, 2019

Closer to a Cure: NEW Success with Anti-Cancer Human Study

Jeff Nielson February 14, 2019

Patient Five Cancer-Free Twelve Months After Single Anti-Cancer Treatment

Accesswire January 31, 2019

Patient Six Cancer-Free at Nine Months After Single Anti-Cancer Treatment

Accesswire January 30, 2019